Effects of a CB1 Antagonist/Inverse Agonist (Rimonabant) on Functional Recovery in Stroke Patients During Subacute Phase.
Key facts
- Where
- Albacete, Badalona, Brunete, Cordoba és Madrid, SpanyolországSee the 6 sites
- Phase
- 2. fázis
Where in Spanyolország
- Hospital General Universitario de AlbaceteAlbacete, SpanyolországToborzás még nem indult
- Fundacio Institut GuttmannBadalona, SpanyolországToborzás még nem indult
- Silvia Beatriz S.L.Brunete, SpanyolországToborzás még nem indult
- Jimenez Lucena S.L.Cordoba, SpanyolországToborzás még nem indult
- Hospital Clínico San CarlosMadrid, SpanyolországToborzás még nem indult
- Hospital Universitario La PazMadrid, SpanyolországToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sinfatin S.L.
- Trial code
- EU 2025-521689-86-00
- Record updated
- 2026. augusztus 10.
- Original description
To evaluate the effect of rimonabant in improving functional independence in post-stroke patients in subacute phase.Read full original descriptionShow less
Effects of a CB1 Antagonist/Reverse Agonist (Rimonabant) on Functional Recovery in Stroke Patients During Subacute Phase.
To evaluate the effect of rimonabant in improving functional independence in post-stroke patients in subacute phase.
Inclusion: Age between 18 and 75 years; Between 14 days and 3 months (14 – 90 days) since the stroke; Modified Rankin Scale (mRS) score between 2 and 4; Barthel Index (BI) score ≤ 70 at screening; Capacity to provide informed consent.
Exclusion: Participation in another clinical trial with pharmacological intervention the month prior to enrolment; History of severe psychiatric disorders, major depression or prior suicide attempts; Treatment with anticoagulants or strong CYP3A4 inhibitors or inducers (inhibitors such as ketoconazole, itraconazole, ritonavir, telithromycin, clarithromycin, or nefazodone, and inducers such as rifampicin, phenytoin, phenobarbital, carbamazepine, or St. John's Wort); Known allergy to Rimonabant or any of the excipients used; Any other condition that, in the opinion of the investigator, makes the subject's participation in the study inadvisable, such as severe heart failure or uncontrolled diabetes; Patients with a history of ischemic or haemorrhagic stroke resulting in a residual mRS > 1, or with a pre-existing mRS > 1 due to other medical conditions; Fertile men or women who cannot guarantee the use of highly effective contraceptive methods, as defined by the European HMA-CTFG guidelines—i.e., those with a failure rate of less than 1 % per year when used consistently and correctly; Uncontrolled hypothyroidism, or a history of severe bone, liver, or kidney disease; High suicide risk assessed by C-SSRS; Body Mass Index > 40 kg/m2; Pregnancy or breastfeeding; Inability to attend hospital visits.